NCT03803514View on ClinicalTrials.gov

Effect of rEPO in FGF23 in ESRD Patients

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

March 31, 2019

Study Completion Date

October 20, 2019

Conditions
AnemiaChronic Kidney Diseases
Interventions
DRUG

Recombinant EPO

Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.

Trial Locations (1)

Unknown

Hospital Clinico Universidad de Chile, Santiago

All Listed Sponsors
lead

University of Chile

OTHER

NCT03803514 - Effect of rEPO in FGF23 in ESRD Patients | Biotech Hunter | Biotech Hunter